

Clinical trials of antithrombotics for peripheral vascular diseases in all type of patients

TrialResults-center www.trialresultscenter.org

1 anticoagulant

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|-----------------------------------|
| vs | | | |
| WAVE <i>ongoing</i> n=NA | - | - | |
| acenocoumarol vs placebo | | | |
| APIC , 1989 n=72/74 follow-up: 1 an | Acenocoumarol INR 2-4.5 versus Placebo | AOMI syade II | Factorial plan Simple aveugle |
| phenprocoumon vs placebo | | | |
| De Smit , 1987 n=155/145 follow-up: 5 ans | Phenprocoumon INR 2.8-4.8 versus Placebo | AOMI de stade II (stades III et IV : 7%) | Parallel groups Double aveugle |

References

WAVE, 0:

The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. *Am Heart J* 2006 Jan;151:1-9 [[16368284](#)]

APIC, 1989:

Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. Dettori AG, Pini M, Moratti A, Paolicelli M, Basevi P, Quintavalla R, Manotti C, Di Lecce C *Angiology* 1989 Apr;40:237-48 [[2650578](#)]

De Smit, 1987:

De Smit P, Van Urk H. Dutch oral anticoagulant trial. *Acta Chir Austriaca* 1992; 24:5-7.

2 heparin

| Trial | Treatments | Patients | Trials design and methods |
|--|--------------------------------------|---------------|-----------------------------------|
| HNF vs placebo | | | |
| Tesi , 1989 n=10/10 follow-up: 6 mois | HBPM 8000 U / j versus Placebo | AOMI stade II | Parallel groups Double aveugle |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---------------|-----------------------------------|
| Antonicelli , 1999 n=101/100 follow-up: 3 mois | Hparine calcique 12500 IU / j versus Placebo | AOMI stade II | Parallel groups Double aveugle |
| LMWH vs placebo | | | |
| Mannarino , 1991 n=22/22 follow-up: 6 mois | Hparine de bas poids molculaire(PM= 5000 Dalton), 15000 U od sc versus Placebo en seringues ppremlies de mme aspect que le traitement | AOMI stade II | Parallel groups Double aveugle |
| Calabro , 1993 n=18/18 follow-up: 6 mois | Hparine de bas poids molculaire versus Placebo | AOMI stade II | Parallel groups Double aveugle |

References

Tesi, 1989:

Tesi M, Bronchi GF, Carini A, Morfini M, Cinotti S, Filiberti E. Efficacy and safety of a new low molecular weight heparin in the medium- term treatment of atherosclerotic arteriopathy of the lower limbs. J Drug Dev 1989; 2(2):73-82.

Antonicelli, 1999:

Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication. Italian CAP Study Group. Antonicelli R, Sardina M, Scotti A, Bonizzoni E, Paciaroni E Am J Med 1999 Sep;107:234-9 [10492316]

Mannarino, 1991:

Mannarino E, Pasqualini L, Innocente S, Orlandi U Efficacy of low molecular weight heparin in the management of intermittent claudication Angiology 1991;42:1-7

Calabro, 1993:

Alessio Calabro, Francesco Piarulli, Daniele Milan,Alberto Rossi, Giovanna Coscetti Clinical assessment of low molecular weight heparin . Effects in peripheral vascular disease angiology 1993;44:188-195

3 platelet aggregation inhibitors

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|--|
| aspirin vs placebo | | | |
| CLIPS , 2007 n=185/181 follow-up: 20.7 months mean | oral aspirin 100 mg daily versus placebo | outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6 | Factorial plan double blind Europe |

References

CLIPS, 2007:

Catalano M, Born G, Peto R Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007

4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.